Phase 4 Glaucoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older who have been diagnosed with mild to moderate open-angle glaucoma (a common type of glaucoma where fluid drains too slowly from the eye)
- People who are currently using a specific combination of two eye drop medications — Cosopt and Latanoprost — as prescribed, for at least 1 month
- People who have signs of damage to the optic nerve (the nerve connecting the eye to the brain), confirmed using standard eye care guidelines
- People who have reliable and repeatable visual field test results (tests that measure your range of vision) showing damage consistent with glaucoma
- People whose eye pressure (the fluid pressure inside the eye) is between 18 and 28 mmHg in at least one eye, with no more than a 5 mmHg difference between the two eyes
- People whose corneal thickness (the thickness of the clear front surface of the eye) measures between 450 and 650 µm (micrometres)
Who may not be able to join:
- People who have had any eye procedure or eye surgery within the past year (for example, cataract surgery)
- People who have previously had glaucoma surgery or laser treatment, unless they had a specific laser procedure called SLT more than 1 year ago
- People who are allergic to or cannot use any of the study medications: Rocklatan, Simbrinza, Cosopt, or Latanoprost, or similar types of drugs
- People with an uncontrolled serious health condition that the trial doctor believes could make participation unsafe or difficult
- People with significant eye conditions (such as corneal diseases or abnormalities) that could affect accurate eye pressure readings
- People whose eye pressure was not controlled even when using either of these two-drug combinations before
- People with significant eye surface problems (such as redness or irritation) found during an eye examination
- People who regularly take certain systemic (whole-body) medications that may affect eye pressure
- People who are pregnant, breastfeeding, or planning to become pregnant
- People who, in the trial doctor's opinion, have any condition that might affect the study results (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Sandra Yeh, MD, Prairie Eye Center
Phone: 217-257-3102
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Decrease in mean diurnal IOP
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.